35 related articles for article (PubMed ID: 38745669)
1. Association between serum IgG concentrations and the incidence of infections in patients with chronic lymphocytic leukemia and secondary immunodeficiency under treatment with Privigen.
Otremba B; Haslbauer F; Reiser M; Weide R; Obermeier M; Pfründer D
Int J Clin Pharmacol Ther; 2024 Jun; 62(6):241-249. PubMed ID: 38577752
[TBL] [Abstract][Full Text] [Related]
2. Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis.
Brazel D; Grant C; Cabal A; Chen WP; Pinter-Brown L
Front Immunol; 2024; 15():1334899. PubMed ID: 38745669
[TBL] [Abstract][Full Text] [Related]
3. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.
Kyriakidis I; Mantadakis E; Stiakaki E; Groll AH; Tragiannidis A
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291806
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma as an Exclusion Criteria for CVID Diagnosis Revisited.
Allain V; Grandin V; Meignin V; Bertinchamp R; Boutboul D; Fieschi C; Galicier L; Gérard L; Malphettes M; Bustamante J; Fusaro M; Lambert N; Rosain J; Lenoir C; Kracker S; Rieux-Laucat F; Latour S; de Villartay JP; Picard C; Oksenhendler E
J Clin Immunol; 2023 Jan; 43(1):181-191. PubMed ID: 36155879
[TBL] [Abstract][Full Text] [Related]
5. Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.
Guevara-Hoyer K; Fuentes-Antrás J; de la Fuente-Muñoz E; Fernández-Arquero M; Solano F; Pérez-Segura P; Neves E; Ocaña A; Pérez de Diego R; Sánchez-Ramón S
Front Immunol; 2022; 13():937872. PubMed ID: 35990641
[TBL] [Abstract][Full Text] [Related]
6. The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma.
Fischer T; Ni A; Bantilan KS; Soumerai JD; Alperovich A; Batlevi C; Younes A; Zelenetz AD
Leuk Lymphoma; 2022 Mar; 63(3):573-582. PubMed ID: 35109746
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Baseline Immunologic Profile in Aggressive B-cell non-Hodgkin's Lymphomas.
Ramadan S; Ceparano G; Cignetti A; Sammassimo S; Bagnardi V; Pagan E; Gottardi D; Fiori S; Passerini R; Radice T; Saglio G; Tarella C
Mediterr J Hematol Infect Dis; 2021; 13(1):e2021018. PubMed ID: 33747399
[TBL] [Abstract][Full Text] [Related]
8. The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma.
Pan BH; Kong YL; Wang L; Zhu HY; Li XT; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Leuk Lymphoma; 2021 Feb; 62(2):291-299. PubMed ID: 33063579
[TBL] [Abstract][Full Text] [Related]
9. Lymphoproliferative Disease in CVID: a Report of Types and Frequencies from a US Patient Registry.
Yakaboski E; Fuleihan RL; Sullivan KE; Cunningham-Rundles C; Feuille E
J Clin Immunol; 2020 Apr; 40(3):524-530. PubMed ID: 32185577
[TBL] [Abstract][Full Text] [Related]
10. Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.
Kyriakidis I; Tragiannidis A; Zündorf I; Groll AH
Mycoses; 2017 Aug; 60(8):493-507. PubMed ID: 28444889
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab.
Filanovsky K; Miller EB; Sigler E; Berrebi A; Shvidel L
Recent Pat Anticancer Drug Discov; 2016; 11(2):228-35. PubMed ID: 26825174
[TBL] [Abstract][Full Text] [Related]
12. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
De Angelis F; Tosti ME; Capria S; Russo E; D'Elia GM; Annechini G; Stefanizzi C; Foà R; Pulsoni A
Leuk Res; 2015 Dec; 39(12):1382-8. PubMed ID: 26547259
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.
Carulli G; Ottaviano V; Sammuri P; Domenichini C; Guerri V; Rousseau M; Ciancia EM; Ciabatti E; Petrini M
Int J Hematol; 2015 Jul; 102(1):59-66. PubMed ID: 25953308
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.
Goede V; Klein C; Stilgenbauer S
Oncol Res Treat; 2015; 38(4):185-92. PubMed ID: 25877943
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
16. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.
Makatsori M; Kiani-Alikhan S; Manson AL; Verma N; Leandro M; Gurugama NP; Longhurst HJ; Grigoriadou S; Buckland M; Kanfer E; Hanson S; Ibrahim MA; Grimbacher B; Chee R; Seneviratne SL
QJM; 2014 Oct; 107(10):821-8. PubMed ID: 24778295
[TBL] [Abstract][Full Text] [Related]
17. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
Casulo C; Maragulia J; Zelenetz AD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):106-11. PubMed ID: 23276889
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
Barth MJ; Hernandez-Ilizaliturri FJ; Mavis C; Tsai PC; Gibbs JF; Deeb G; Czuczman MS
Br J Haematol; 2012 Feb; 156(4):490-8. PubMed ID: 22150234
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
